Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study.
Antiangiogenesis
Antiresorptive
Comprehensive dental care
Dental extraction
Medication-related osteonecrosis of the jaw bones
Preventive dental methods
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
28
05
2024
accepted:
18
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Medication-related osteonecrosis of the jaw bones (MRONJ) is a well-known complication of antiresorptive and antiangiogenic drugs. Since the first report, more occurrences of MRONJ have been described worldwide. Dental extraction has been described by many studies as one of the risk factors for MRONJ. Comprehensive dental care (CDC) is a preventive dental method provided to patients prior to drug commencement. This study aims to determine the association between CDC and MRONJ. A retrospective analysis was performed on 75 medical records of patients on antiresorptive and/or antiangiogenic drugs between February 2018 and May 2021. Demographics and clinical and radiographic data were collected. Univariate and multivariate analyses were performed to determine the factors associated with MRONJ. Of the 75 patients who met the inclusion criteria, 11 (14.7%) developed MRONJ. Three out of 11 patients (27.2%) developed MRONJ spontaneously, while eight patients (72.8%) developed it after trauma from dentures or dental extractions. Following a binary logistic regression analysis, the lack of CDC was identified as a significant predictor of MRONJ. Patients who did not receive CDC had an odds ratio of 8.64 (95% confidence interval (CI): 1.27-58.62, p = 0.03). However, dental extraction did not show a statistically significant association with MRONJ in both the univariate and multivariate analyses. CDC before treatment with antiresorptive and antiangiogenic drugs is a potentially effective preventive method for reducing MRONJ. Dental extraction was not a significant factor in relation to MRONJ.
Identifiants
pubmed: 39455955
doi: 10.1186/s12903-024-05081-0
pii: 10.1186/s12903-024-05081-0
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bone Density Conservation Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1291Informations de copyright
© 2024. The Author(s).
Références
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw–2014 Update. J Oral Maxillofac Surg. 2014;72(10):1938–56.
pubmed: 25234529
doi: 10.1016/j.joms.2014.04.031
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5)9:20–943.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled Phase III Trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–7.
pubmed: 21986094
doi: 10.1093/annonc/mdr435
Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, et al. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021;11(1):17226.
pubmed: 34446755
pmcid: 8390686
doi: 10.1038/s41598-021-96480-8
Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(6):477–85.
pubmed: 30249535
doi: 10.1016/j.oooo.2018.08.015
Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: A nationwide population-based study in Japan. J Oral Maxillofac Surg. 2022;80(4):714–27.
pubmed: 35033505
doi: 10.1016/j.joms.2021.12.007
Coropciuc R, Coopman R, Garip M, Gielen E, Politis C, Van den Wyngaert T, et al. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients. Bone. 2023;170:116722.
pubmed: 36858337
doi: 10.1016/j.bone.2023.116722
Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S, et al. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLoS ONE. 2018;13(7): e0201343.
pubmed: 30048523
pmcid: 6062135
doi: 10.1371/journal.pone.0201343
Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43:847–54.
pubmed: 25958767
doi: 10.1016/j.jcms.2015.03.039
Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: A multicenter retrospective study. Osteoporos Int. 2019;30(1):231–9.
pubmed: 30406309
doi: 10.1007/s00198-018-4746-8
Bolette A, Lecloux G, Rompen E, Albert A, Kerckhofs G, Lambert F. Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats. J Craniomaxillofac Surg. 2019;47(2):349–56.
pubmed: 30595476
doi: 10.1016/j.jcms.2018.08.011
Hadaya D, Soundia A, Gkouveris I, Dry SM, Aghaloo TL, Tetradis S. Development of medication-related osteonecrosis of the jaw after extraction of teeth with experimental periapical disease. J Oral Maxillofac Surg. 2019;77(1):71–86.
pubmed: 30218655
doi: 10.1016/j.joms.2018.08.010
Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V, et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022;30(8):6429–40.
pubmed: 35292850
pmcid: 9213300
doi: 10.1007/s00520-022-06940-8
Drudge-Coates L, Van den Wyngaert T, Schiødt M, van Muilekom HAM, Demonty G, Otto S. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: A practical guide for nurses and other allied healthcare professionals. Support Care Cancer. 2020;28(9):4019–29.
pubmed: 32307659
pmcid: 7378104
doi: 10.1007/s00520-020-05440-x
Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience. Ann Oncol. 2012;23(1):193–200.
pubmed: 21427065
doi: 10.1093/annonc/mdr039
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270–90.
pubmed: 31329513
doi: 10.1200/JCO.19.01186
Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com , updated 2013/04/06, accessed 2023/09/06.
Berg BI, Mueller AA, Augello M, Berg S, Jaquiéry C. Imaging in patients with bisphosphonate-associated osteonecrosis of the jaws (MRONJ). Dentistry J. 2016;4(3):29.
doi: 10.3390/dj4030029
Cardoso CL, Barros CA, Curra C, Fernandes LM, Franzolin SO, Júnior JS, et al. Radiographic findings in patients with medication-related osteonecrosis of the jaw. Int J Dent. 2017;2017:3190301.
pubmed: 28352284
pmcid: 5352898
doi: 10.1155/2017/3190301
Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
pubmed: 19087314
pmcid: 2633005
doi: 10.1186/1751-0473-3-17
Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. Oral Oncol. 2018;85:15–23.
pubmed: 30220314
doi: 10.1016/j.oraloncology.2018.08.003
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117–20.
pubmed: 18689864
doi: 10.1093/annonc/mdn554
Oteri G, De Ponte FS, Runci M, Peditto M, Marcianò A, Cicciù M. Oral-health-related quality of life after surgical treatment of osteonecrosis of the jaws. J Craniofac Surg. 2018;29(2):403–8.
pubmed: 29135723
doi: 10.1097/SCS.0000000000004087
Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, et al. Medication-related osteonecrosis of the jaw: An update on the Memorial Sloan Kettering Cancer Center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):440–5.
pubmed: 29580668
pmcid: 7518027
doi: 10.1016/j.oooo.2018.02.003
Cunha RCD da, Sousa RVde, Ribeiro PJT. Prevention and treatment of medication-related osteonecrosis of the jaw: an integrative review. Research, Society and Development. 2022;11(8):e1011830539.
Bacci C, Cerrato A, Bardhi E, Frigo AC, Djaballah SA, Sivolella S. A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities. Support Care Cancer. 2022;30(2):1723–9.
pubmed: 34580783
doi: 10.1007/s00520-021-06587-x
Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention. Biomed Res Int. 2018;16:2684924.
Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014;72(4):655–7
pubmed: 24480762
doi: 10.1016/j.joms.2013.12.007
Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137–45.
Otsuru M, Fujiki Y, Soutome S, Nakamura N, Miyoshi T, Naruse T, et al. Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents. J Dent Sci. 2024;19(1):203–10.
pubmed: 38303840
doi: 10.1016/j.jds.2023.04.026
Khoo SC, Nabil S, Fauzi AA, Yunus SSM, Ngeow WC, Ramli R. Predictors of osteoradionecrosis following irradiated tooth extraction. Radiat Oncol. 2021;16(1):130.
pubmed: 34261515
pmcid: 8278595
doi: 10.1186/s13014-021-01851-0
Nobuto T, Imai H, Suwa F, Kono T, Suga H, Jyoshi K, et al. Microvascular response in the periodontal ligament following mucoperiosteal flap surgery. J Periodontol. 2003;74(4):521–8.
pubmed: 12747458
doi: 10.1902/jop.2003.74.4.521
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24(4):527–36.
pubmed: 28656643
doi: 10.1111/odi.12708
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356–62.
pubmed: 19805682
doi: 10.1200/JCO.2009.21.9584
Hallmer F, Bjørnland T, Andersson G, Becktor JP, Kristoffersen AK, Enersen M. Bacterial diversity in medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(4):436–44.
pubmed: 28159588
doi: 10.1016/j.oooo.2016.11.011
Kos M, Junka A, Smutnicka D, Bartoszewicz M, Kurzynowski T, Gluza K. Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2013;71(6):1010–6.
Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J, Tominaga K. Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg. 2013;42(11):1481–7.
pubmed: 23932020
doi: 10.1016/j.ijom.2013.06.011
Otto S, Pautke C, Martin Jurado O, Nehrbass D, Stoddart MJ, Ehrenfeld M, et al. Further development of the MRONJ minipig large animal model. J Craniomaxillofac Surg. 2017;45(9):1503–14.
pubmed: 28803745
doi: 10.1016/j.jcms.2017.07.002
Lesclous P, Cloitre A, Catros S, Devoize L, Louvet B, Châtel C, et al. Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis. Bone. 2020;137:115412.
pubmed: 32404281
doi: 10.1016/j.bone.2020.115412
Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, et al. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021;29(5):2305–17.
pubmed: 33190182
doi: 10.1007/s00520-020-05882-3
Lee S, Ku Mat Yazid, KNDW, Chan SW, Ripen ZM. Prevalence of osteonecrosis of the jaw in Faculty of Dentistry, University of Malaya from year 2010–2020. 13th National Dental Students' Scientific Conference 2021, Faculty of Dentistry, Segi University (29 May 2021).
Jeong HG, Hwang JJ, Lee JH, Kim YH, Na JY, Han SS. Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent. 2017;47(1):45–50
pubmed: 28361029
pmcid: 5370245
doi: 10.5624/isd.2017.47.1.45
Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243–53.
pubmed: 19772941
doi: 10.1016/j.joms.2009.03.050
Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):509–16.
pubmed: 20674404
doi: 10.1016/j.tripleo.2010.04.023
Khominsky A, Lim M. “Spontaneous” medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018;63(4):441–54.
pubmed: 30144095
doi: 10.1111/adj.12648
Manley BJ, Neal TW, Indrakanti S, Schlieve T. Spontaneous medication-related osteonecrosis of the jaws in a 23-year-old. Oral and Maxillofacial Surgery Cases. 2023;9(1):100289.
doi: 10.1016/j.omsc.2022.100289
Farah CS, Savage NW. Oral ulceration with bone sequestration. Aust Dent J. 2003;48(1):61–4.
pubmed: 14640160
doi: 10.1111/j.1834-7819.2003.tb00011.x
Sonnier KE, Horning GM. Spontaneous bony exposure: a report of 4 cases of idiopathic exposure and sequestration of alveolar bone. J Periodontol. 1997;68:758–62.
pubmed: 9287067
doi: 10.1902/jop.1997.68.8.758
Woolley J, Akintola O, Yates J, Calasans-Maia MD, de Albuquerque C-M, Kocherhina I, Sacco R. The risk of osteonecrosis of the jaw and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment: A systematic review. Heliyon. 2021;7(1):e05914.
pubmed: 33490677
pmcid: 7810783
doi: 10.1016/j.heliyon.2021.e05914
Oral Health Division. National Oral Health Survey of Adults 2010 (NOHSA 2010). Ministry of Health Malaysia; 2013.